FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
haura nor raananaa	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Carvajal Alejandra  (Last) (First) (Middle)  C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET  (Street)  CAMBRIDGE MA 02142  (City) (State) (Zip)						2. Issuer Name and Ticker or Trading Symbol MOMENTA PHARMACEUTICALS INC [MNTA]  3. Date of Earliest Transaction (Month/Day/Year) 10/17/2018  4. If Amendment, Date of Original Filed (Month/Day/Year)									Relationship of Reporting Person(s) to Issuer eck all applicable)  Director 10% Owner X Officer (give title Other (speci below) below)  Chief Legal Officer  Individual or Joint/Group Filing (Check Applicate)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				wner specify pplicable
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)  Table II - Derivati					tion ny/Year) tive Se	ion 2A. Deemed Execution Date,			3. Transacti Code (Ins 8) Code	on str. V	4. Secu Dispos and 5)  Amoun	rities Acqued Of (D) (	or Price	or 4	5. Amo Securit Benefic Owned Follow Report Transa (Instr. 3	Amount of Curities For (D)		m: Direct or irect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	n 3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In	Fransaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, and 5)		ber ive ies ed ed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Expiration Date Expiration			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Numbio of Title Shares		8. of De Se (In	Price rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	(1)	10/17/2018			A		39,000		(2)		(2)	Common Stock	39,00	0	\$0	39,000		D	

## **Explanation of Responses:**

- 1. Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock.
- 2. Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.

/s/ R. Mark Chamberlin as attorney in fact

10/19/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.